Literature DB >> 25774965

Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Xiufeng Wu1, Arlene J Sereno, Flora Huang, Steven M Lewis, Ricky L Lieu, Caroline Weldon, Carina Torres, Cody Fine, Micheal A Batt, Jonathan R Fitchett, Andrew L Glasebrook, Brian Kuhlman, Stephen J Demarest.   

Abstract

A myriad of innovative bispecific antibody (BsAb) platforms have been reported. Most require significant protein engineering to be viable from a development and manufacturing perspective. Single-chain variable fragments (scFvs) and diabodies that consist only of antibody variable domains have been used as building blocks for making BsAbs for decades. The drawback with Fv-only moieties is that they lack the native-like interactions with CH1/CL domains that make antibody Fab regions stable and soluble. Here, we utilize a redesigned Fab interface to explore 2 novel Fab-based BsAbs platforms. The redesigned Fab interface designs limit heavy and light chain mixing when 2 Fabs are co-expressed simultaneously, thus allowing the use of 2 different Fabs within a BsAb construct without the requirement of one or more scFvs. We describe the stability and activity of a HER2×HER2 IgG-Fab BsAb, and compare its biophysical and activity properties with those of an IgG-scFv that utilizes the variable domains of the same parental antibodies. We also generated an EGFR × CD3 tandem Fab protein with a similar format to a tandem scFv (otherwise known as a bispecific T cell engager or BiTE). We show that the Fab-based BsAbs have superior biophysical properties compared to the scFv-based BsAbs. Additionally, the Fab-based BsAbs do not simply recapitulate the activity of their scFv counterparts, but are shown to possess unique biological activity.

Entities:  

Keywords:  BiTE, bispecific T cell engager; BsAb, bispecific antibody; CD, circular dichroism; DSC, differential scanning calorimetry; Fab interface design; Fab, antigen binding antibody fragment; Fv, variable domains antibody fragment; HC, antibody heavy chain; IgG-Fab; LC, antibody light chain; LCMS, liquid chromatography with in-line mass spectrometry; SEC-LC, size exclusion chromatography with in-line static light scattering; T cell; Tm, temperature at the midpoint of thermal unfolding; bispecific antibody; mAb, monoclonal antibody; scFv, single chain Fv; tandem Fab

Mesh:

Substances:

Year:  2015        PMID: 25774965      PMCID: PMC4622572          DOI: 10.1080/19420862.2015.1022694

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  47 in total

1.  A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism.

Authors:  Zhi Liu; Esther C Leng; Kannan Gunasekaran; Martin Pentony; Min Shen; Monique Howard; Janelle Stoops; Kathy Manchulenko; Vladimir Razinkov; Hua Liu; William Fanslow; Zhonghua Hu; Nancy Sun; Haruki Hasegawa; Rutilio Clark; Ian N Foltz; Wei Yan
Journal:  J Biol Chem       Date:  2015-01-12       Impact factor: 5.157

2.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 3.  Bispecific antibodies engage T cells for antitumor immunotherapy.

Authors:  Bryan D Choi; Mingqing Cai; Darell D Bigner; Ankit I Mehta; Chien-Tsun Kuan; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2011-03-30       Impact factor: 4.388

Review 4.  Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.

Authors:  John V Heymach; Monique Nilsson; George Blumenschein; Vassiliki Papadimitrakopoulou; Roy Herbst
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

5.  Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2.

Authors:  Christian Jost; Johannes Schilling; Rastislav Tamaskovic; Martin Schwill; Annemarie Honegger; Andreas Plückthun
Journal:  Structure       Date:  2013-10-03       Impact factor: 5.006

Review 6.  Single chain antibody variable regions.

Authors:  R E Bird; B W Walker
Journal:  Trends Biotechnol       Date:  1991-04       Impact factor: 19.536

Review 7.  Blinatumomab: a historical perspective.

Authors:  Dirk Nagorsen; Peter Kufer; Patrick A Baeuerle; Ralf Bargou
Journal:  Pharmacol Ther       Date:  2012-08-24       Impact factor: 12.310

8.  Crystal structure of a diabody, a bivalent antibody fragment.

Authors:  O Perisic; P A Webb; P Holliger; G Winter; R L Williams
Journal:  Structure       Date:  1994-12-15       Impact factor: 5.006

9.  A recombinant immunotoxin containing a disulfide-stabilized Fv fragment.

Authors:  U Brinkmann; Y Reiter; S H Jung; B Lee; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 12.779

10.  Improving target cell specificity using a novel monovalent bispecific IgG design.

Authors:  Yariv Mazor; Vaheh Oganesyan; Chunning Yang; Anna Hansen; Jihong Wang; Hongji Liu; Kris Sachsenmeier; Marcia Carlson; Dhanesh V Gadre; Martin Jack Borrok; Xiang-Qing Yu; William Dall'Acqua; Herren Wu; Partha Sarathi Chowdhury
Journal:  MAbs       Date:  2015       Impact factor: 5.857

View more
  25 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.

Authors:  Shiyong Gong; Fang Ren; Danqing Wu; Xuan Wu; Chengbin Wu
Journal:  MAbs       Date:  2017-07-10       Impact factor: 5.857

3.  CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.

Authors:  Anke Steinmetz; François Vallée; Christian Beil; Christian Lange; Nicolas Baurin; Jochen Beninga; Cécile Capdevila; Carsten Corvey; Alain Dupuy; Paul Ferrari; Alexey Rak; Peter Wonerow; Jochen Kruip; Vincent Mikol; Ercole Rao
Journal:  MAbs       Date:  2016-03-16       Impact factor: 5.857

Review 4.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

5.  Engineering Polymer-Binding Bispecific Antibodies for Enhanced Pretargeted Delivery of Nanoparticles to Mucus-Covered Epithelium.

Authors:  Justin T Huckaby; Christina L Parker; Tim M Jacobs; Alison Schaefer; Daniel Wadsworth; Alexander Nguyen; Anting Wang; Jay Newby; Samuel K Lai
Journal:  Angew Chem Int Ed Engl       Date:  2019-03-21       Impact factor: 15.336

6.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

7.  Engineering tetravalent IgGs with enhanced agglutination potencies for trapping vigorously motile sperm in mucin matrix.

Authors:  Bhawana Shrestha; Alison Schaefer; Elizabeth C Chavez; Alexander J Kopp; Timothy M Jacobs; Thomas R Moench; Samuel K Lai
Journal:  Acta Biomater       Date:  2020-09-13       Impact factor: 8.947

8.  Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy.

Authors:  Wentao Chen; Kurt Yun Mou; Paige Solomon; Rahul Aggarwal; Kevin K Leung; James A Wells
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-26       Impact factor: 12.779

9.  Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.

Authors:  Mathilde Poussin; Arlene Sereno; Xiufeng Wu; Flora Huang; Jason Manro; Shanshan Cao; Carmine Carpenito; Andrew Glasebrook; Daniel J Powell; Stephen Demarest
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

10.  Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.

Authors:  Jan P Bogen; Stefania C Carrara; David Fiebig; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.